SMi’s 5th Drug Safety conference and workshop will be taking place this June in London, UK. Gain insights into patient support programmes (PSP), signal detection and management, pharmacovigilance stakeholder management and explore the future of clinical trial regulations, presented to you by the MHRA.

This Week’s Spotlight: Accord Healthcare, Takeda and Sanofi

 Managing Data & Communicating It With The Public:

As the world’s population increases and emerging markets in developing countries are also increasing the demand for medicine, the intrusion of counterfeit drugs has burgeoned as well.  It is now recognized that the safety of medicines is the responsibility of all stakeholders – the pharmaceutical companies, the government drug regulation agencies, healthcare professionals (HCPs), and patients. As clinical research and development of drugs is becoming increasingly regulated, contract research organizations (CROs) and sites (that is, clinics, hospitals, and communities where clinical trials are conducted) and even customs administrations, are now also considered stakeholders.*

Hear from: Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare, as she presents: ‘Pharmacovigilance Stakeholder Management – How we Manage the Interactions the PV Department has, Internally and Externally.’Day 1 | @14:40


Spotlight Presentation:

There are three general lines of attack in achieving the capabilities required to meet today’s challenging business needs: internal optimization, consolidation, and outsourcing. Most organizations have found that a mix of all three is required to strike the right balance of benefits and risk

Although elements of PV have been outsourced for a number of years, its efficiency and effectiveness has not been ideal and is only now maturing to the point where it can be considered more seriously.*

Hear from: Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda, as he presents: ‘Pharmacovigilance Outsourcing: The Evolving Model.’ – Day 1 | @15:50


Patient Centricity:

Patient-centeredness has become an acknowledged hallmark of not only high-quality health care but also high-quality drug development. Biopharmaceutical companies are actively seeking to be more patient-centric in drug research and development by involving patients in identifying target disease conditions, participating in the design of, and recruitment for, clinical trials, and disseminating study results. Drug safety departments within the biopharmaceutical industry are at a similar inflection point.

Hear from: John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi, as he presents: ‘Effective Communication & Patient Centric Pharmacovigilance’ – Day 1 | @16:30

Further information is available at:

SMi presents the 5th conference on:

Drug Safety 2018

Date: 11th – 12th June 2018

Workshops: 13th June 2018

Location: Holiday Inn Kensington Forum, London UK



*Sources: |



Contact Information:

For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email:

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at